X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Lupin: Exploring new vistas - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Lupin: Exploring new vistas

Feb 22, 2002

Lupin Ltd. seems to be undergoing a drastic change in its business model. While retaining its focus on the anti-TB segment, the company seems to be making all efforts to become a recognised global player in the Cephalosporin segment and is now considering research as a new thrust area. Strategy for entering the generics business also seems to be in place. The company's business is being restructured to exit competitive segments and enter high margin segments. The merger with Lupin Chemicals has helped the company catapult into the league of few companies in India with Rs 10 bn plus revenues. Secondly, it has helped the company consolidate its strong position in the anti-TB business. While Lupin Chemicals manufactured Rifampicin, Lupin Labs manufactured Ethambutol. Together both these molecules command almost the entire anti-TB market. The consolidation helped the company in becoming a world leader in the anti-TB market, with a share of more than 40% in the domestic anti-TB market, estimated at Rs 3.3 bn. In a segment, which registered de-growth in last two years, Lupin managed to record a double-digit growth.

The company is also aggressively launching new products to reduce its therapeutic segment dependence. The company has launched new products in cardiovascular, cephalosporin and herbal segments. It has already launched 10 products in the year with plans for another 10 products. Lupin plans to introduce 70-80 products in the span of 3 years, which should reduce its dependence on the anti-TB segment.

Exports currently contribute around 24% of the company's total turnover. Going forward, Cephalosporins would be a key focus area for exports. The company is planning partnership route to enter the generic market by tying up with large generic companies in the US/ Europe. In the generic business, the company has tied up with three generic marketing companies viz, Merck Generics, ABP and Apcotex. Lupin would be supplying bulk Cefuroxime Axetil to Apotex, which is the sole generic competitor to Ranbaxy (at least till mid 2003). It may be recalled that Ranbaxy recently received approval for selling this drug. Apcotex’s approval is expected by July'02. We expect US$ 5 m revenues to Lupin from this agreement.

Though late, Lupin is now recognizing R&D as a thrust area. The company has established state-of-the-art R&D centre spread over an area of 19 acres at Pune at a cost of over Rs 500 m. The research activity of the company is focused in a manner so as to provide solutions to both immediate and post 2005 research requirements. Lupin has 6 molecules in the pipeline both on NCE and NDDS platform. However, all the molecules are in early pre-clinical stages and it would take time (atleast late 2003) before one can expect revenues from out licensing. Lupin plans to launch 4-6 ANDA's for the US markets this year, with a target of creating a product basket of 25 products over 3 years.

Lupin Ltd- Operating Margins show an up trend
Particulars 3QFY01 3QFY02 9m FY01 9m FY02
Sales (Rs m) 2,336 2,411 7,054 7,163
Sales Growth (%) NA 3.2% NA 1.5%
Operating Margins (%) 18.4% 22.1% 18.8% 21.0%
Net Profit Growth (%) 8.1% 7.7% 8.1% 8.1%

The company has declared marginal sales growth for the nine months ended December' 01. The low growth rate seems to be on the back of the company exiting from low margins (particularly bulk drugs) business. What is encouraging is the rise in operating margins. We expect margins to move up further, as the contribution of exports to total sales improves. Topline is also expected to register respectable growth with the Cephalosporins facility commencing production.

At the current market price of Rs 121, the stock is trading at 6.5x its annualised earnings for 9mFY02. The current acceleration in its research initiatives, sales and margins growth and breakthrough in the generics business are expected to prove as triggers for the stock in the near term. The stock is also attractively priced when compared to its peers. However, a high debt equity ratio of the company remains an area of concern.


Equitymaster requests your view! Post a comment on "Lupin: Exploring new vistas". Click here!

  

More Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

My Top 7 Stocks to Buy as Modi Returns to Power(The 5 Minute Wrapup)

May 23, 2019

The Modi government is all set to come back to power. With a stable government at the centre, how should you play the stock market?

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 27, 2019 03:35 PM

TRACK LUPIN

LUPIN - ADCOCK INGRAM COMPARISON

COMPARE LUPIN WITH

MARKET STATS